<DOC>
	<DOCNO>NCT01874938</DOCNO>
	<brief_summary>The main purpose study evaluate effectiveness LY2875358 participant MET diagnostic positive ( + ) , advance gastric gastroesophageal junction ( GEJ ) cancer .</brief_summary>
	<brief_title>A Study LY2875358 Participants With MET Positive , Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Have diagnosis histopathologically cytologically confirm local and/or advance gastric gastroesophageal junction ( GEJ ) adenocarcinoma unresectable Have receive 2 regimen prior chemotherapy gastric GEJ adenocarcinoma Have presence measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) Have consent provide tissue sample prescreening Determined MET diagnostic positive base upon test tumor sample obtain time enrollment Have discontinue previous treatment cancer , include chemotherapy radiotherapy , least 3 week enrollment recover acute effect therapy Have adequate organ function Male participant : must agree use reliable method birth control donate sperm study least 4 month follow last dose study drug country requirement , whichever long Female participant : woman childbearing potential test negative pregnancy ≤14 day enrollment base serum pregnancy test agree use reliable method birth control study 4 month follow last dose study drug must also breastfeed Have performance status ≤1 Eastern Cooperative Oncology Group ( ECOG ) scale Have estimate life expectancy , judgment investigator , least 12 week Are currently enrol , discontinue within last 21 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Have previously complete withdrawn study study investigate LY2875358 Have active fungal , bacterial , and/or know viral infection Have history New York Heart Association class ≥3 , unstable angina , myocardial infarction ( MI ) 6 month prior study drug administration Have symptomatic central nervous system ( CNS ) malignancy metastasis Have previous concurrent malignancy Have receive liver transplant , liver cirrhosis ChildPugh Stage B C Have correct QT interval ( QTc ) &gt; 470 millisecond ( msec ) screen electrocardiogram ( ECG ) Have receive previous treatment hepatocyte growth factor ( HGF ) /MET target therapeutic Have history radiation therapy involve 25 % bone marrow . Previous radiation therapy allow limited must include whole pelvis radiation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>